MovDisordV3, Main, Exploration, bibRecord, 004048

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

Identifieur interne : 004048 ( Main/Exploration ); précédent : 004047; suivant : 004049

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

Auteurs : Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann [États-Unis] ; Monica A. Burke [États-Unis] ; Carol Jacques [États-Unis] ; Joseph H. Friedman [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-05.

RBID : ISTEX:6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972

Descripteurs français

Pascal (Inist)
- Antipsychotique, Chimiothérapie, Dose faible, Efficacité traitement, Etude cohorte, Long terme, Neuroleptique, Parkinson maladie, Personne âgée, Psychose, Quétiapine.
Wicri :
- topic : Personne âgée.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Antipsychotic, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Chemotherapy, Cohort study, Dibenzothiazepines (adverse effects), Dibenzothiazepines (therapeutic use), Drug Tolerance, Drug‐induced psychosis, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (epidemiology), Dyskinesia, Drug-Induced (etiology), Elderly, Female, Follow-Up Studies, Humans, Levodopa (therapeutic use), Long term, Low dose, Male, Neuroleptic, Outcome Assessment (Health Care), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Psychosis, Psychotic Disorders (drug therapy), Psychotic Disorders (epidemiology), Psychotic Disorders (etiology), Quetiapine, Retrospective Studies, Severity of Illness Index, Treatment efficiency, dementia, long‐term, quetiapine.
MESH :
- chemical , adverse effects : Antipsychotic Agents, Dibenzothiazepines.
- chemical , therapeutic use : Antiparkinson Agents, Antipsychotic Agents, Dibenzothiazepines, Levodopa.
- diagnosis : Dyskinesia, Drug-Induced.
- drug therapy : Parkinson Disease, Psychotic Disorders.
- epidemiology : Dyskinesia, Drug-Induced, Psychotic Disorders.
- etiology : Dyskinesia, Drug-Induced, Psychotic Disorders.
- psychology : Parkinson Disease.
- Aged, Drug Tolerance, Female, Follow-Up Studies, Humans, Male, Outcome Assessment (Health Care), Retrospective Studies, Severity of Illness Index.

Abstract

To evaluate the long‐term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)‐motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L‐dopa) dose of 415 mg/d. Seventy‐eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty‐seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non‐responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95% CI = 1.4–92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07). © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972/fulltext/pdf

DOI: 10.1002/mds.10374

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of quetiapine use for psychosis among parkinsonian patients</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
</author>
<author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
</author>
<author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name>
</author>
<author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10374</idno>
<idno type="url">https://api.istex.fr/document/6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002861</idno>
<idno type="wicri:Area/Istex/Curation">002861</idno>
<idno type="wicri:Area/Istex/Checkpoint">002978</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fernandez H:long:term:outcome</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12722164</idno>
<idno type="wicri:Area/PubMed/Corpus">003796</idno>
<idno type="wicri:Area/PubMed/Curation">003796</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003740</idno>
<idno type="wicri:Area/Ncbi/Merge">000A55</idno>
<idno type="wicri:Area/Ncbi/Curation">000A55</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A55</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fernandez H:long:term:outcome</idno>
<idno type="wicri:Area/Main/Merge">005C71</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0380057</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002464</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000857</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002414</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fernandez H:long:term:outcome</idno>
<idno type="wicri:Area/Main/Merge">005F60</idno>
<idno type="wicri:Area/Main/Curation">004048</idno>
<idno type="wicri:Area/Main/Exploration">004048</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of quetiapine use for psychosis among parkinsonian patients</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2003-05">2003-05</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="510">510</biblScope>
<biblScope unit="page" to="514">514</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972</idno>
<idno type="DOI">10.1002/mds.10374</idno>
<idno type="ArticleID">MDS10374</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antipsychotic</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Cohort study</term>
<term>Dibenzothiazepines (adverse effects)</term>
<term>Dibenzothiazepines (therapeutic use)</term>
<term>Drug Tolerance</term>
<term>Drug‐induced psychosis</term>
<term>Dyskinesia, Drug-Induced (diagnosis)</term>
<term>Dyskinesia, Drug-Induced (epidemiology)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Elderly</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Long term</term>
<term>Low dose</term>
<term>Male</term>
<term>Neuroleptic</term>
<term>Outcome Assessment (Health Care)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Psychosis</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (epidemiology)</term>
<term>Psychotic Disorders (etiology)</term>
<term>Quetiapine</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Treatment efficiency</term>
<term>dementia</term>
<term>long‐term</term>
<term>quetiapine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Dibenzothiazepines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Antipsychotic Agents</term>
<term>Dibenzothiazepines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Tolerance</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Outcome Assessment (Health Care)</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term>
<term>Chimiothérapie</term>
<term>Dose faible</term>
<term>Efficacité traitement</term>
<term>Etude cohorte</term>
<term>Long terme</term>
<term>Neuroleptique</term>
<term>Parkinson maladie</term>
<term>Personne âgée</term>
<term>Psychose</term>
<term>Quétiapine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Personne âgée</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To evaluate the long‐term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)‐motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L‐dopa) dose of 415 mg/d. Seventy‐eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty‐seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non‐responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95% CI = 1.4–92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07). © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Rhode Island</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Rhode Island"><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
</region>
<name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A." last="Burke">Monica A. Burke</name>
<name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name>
<name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004048 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004048 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:6159FF1947C0AC2C81DB7C5DD6A0CC90714C4972
   |texte=   Long‐term outcome of quetiapine use for psychosis among parkinsonian patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.